Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)

Next Previous
Trial Profile

A Phase 1, Single and Multiple-Dose, Open-Label Study in Healthy Subjects to Assess the Effect of the Acid Reducing Agents, Omeprazole (OME) and Famotidine (FAM), on the Pharmacokinetics (PK) of Cenicriviroc Mesylate (CVC)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Nov 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cenicriviroc (Primary) ; Famotidine; Omeprazole
  • Indications Cancer; Diabetic neuropathies; Graft-versus-host disease; HIV-1 infections; Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Primary sclerosing cholangitis
  • Focus Pharmacokinetics
  • Sponsors Tobira Therapeutics

Most Recent Events

  • 21 Nov 2017 Status changed from active, no longer recruiting to completed.
  • 18 Apr 2016 Status changed from recruiting to active, no longer recruiting.
  • 20 Feb 2016 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top